Prognostic analysis and limited efficacy of adjuvant TACE in hepatocellular carcinoma following hepatectomy: a propensity score-matched study
PA-TACE may not extend OS or RFS in HCC patients with BCLC 0/A stage, tumor diameter ≥ 5 cm, or MVI. PA-TACE should be administered with caution, even in HCC patients with BCLC B/C stage.
Authors
- Jiayin Qin (ORCID: https://orcid.org/0000-0002-3777-5673)
- Peng Yi (ORCID: https://orcid.org/0000-0002-9367-8851)
- Bang‐De Xiang (ORCID: https://orcid.org/0000-0002-2758-1437)
- Shuang Shen (ORCID: https://orcid.org/0000-0002-0845-2533)
- Zhesheng Wen (ORCID: https://orcid.org/0000-0002-0065-7542)
- Yifei Feng (ORCID: https://orcid.org/0000-0002-5222-7106)
- Wei Lu (ORCID: https://orcid.org/0000-0003-2383-7084)
Institutions
- Ministry of Education of the People's Republic of China (CN)
- Guangxi Medical University (CN)
- Guangxi Center for Disease Prevention and Control (CN)
- University of South China (CN)
Publication Details
- Journal
- Langenbeck s Archives of Surgery
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1007/s00423-025-03663-2
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- National Natural Science Foundation of China
- National Major Science and Technology Projects of China